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INTRODUCTION: Clinical studies have produced conflicting results on the effects ofmetformin on gastrointestinal cancer
development. We aimed to investigate the association between metformin use and stomach, colon,
liver, and pancreatic cancer development among patients with newly diagnosed, drug-naı̈ve type 2
diabetes.
METHODS: This retrospective study evaluated propensity score-matched patients with newly diagnosed type 2
diabetes from the Korean National Health Insurance Service database. Metformin users were
categorized into tertiles according to the cumulative dose or duration of metformin treatment, and the
risks of gastrointestinal cancers were compared.
RESULTS: Metformin users had reduced risks of developing stomach cancer (hazard ratio [HR]: 0.841, 95%
confidence interval [CI]: 0.797–0.887), colon cancer (HR: 0.865, 95% CI: 0.822–0.91), and liver
cancer (HR: 0.709, 95% CI: 0.675–0.746; P < 0.001). However, metformin users did not have a
reduced overall risk of pancreatic cancer (HR: 1.335, 95% CI: 1.209–1.475; P < 0.001). The risks
tended to decrease at higher cumulative doses and durations of metformin use, with significantly
reduced risks of all 4 cancers at the highest cumulative dose (‡1,200,000mg) and the longest duration
(‡2,000 days) of metformin use.
DISCUSSION: This population-based data suggest that metformin could be associated with reductions in the risks of
stomach, colon, and liver cancers, as well a reduced risk of pancreatic cancer in some subgroups.
Metformin has benefit as a first-line treatment for type 2 diabetes mellitus. A further role in cancer risk
reduction could be studied in controlled trials.
SUPPLEMENTARY MATERIAL accompanies this paper at https://links.lww.com/CTG/A410
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INTRODUCTION
Diabetes mellitus (DM) is a common chronic endocrine disease
that is a known risk factor for many types of cancer. The asso-
ciation between DM and cancer development is associated with
insulin resistance, hyperinsulinemia, and the insulin-like growth
factor (IGF) system (1). DM is known to be associated with
gastrointestinal (GI) cancer, which has high global rates of
incidence and mortality (2). Moreover, the consensus report by
the American Diabetes Association and the American Cancer
Society indicated that DM is associated with an increased risk of
developing cancers involving the liver, pancreas, colon, and rec-
tum (3).
Metformin is the first-line medication for type 2 DM, and
preclinical studies have indicated that it also has anticancer effects
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(4). This drug mainly increases the insulin sensitivity of tissues
and thereby reduces insulin levels (5), although metformin also
activates AMP-activated protein kinase (AMPK). This kinase
negatively regulates themammalian target of rapamycin (mTOR)
pathway, which is known to inhibit protein synthesis and cell
proliferation (6). Previous studies have indicated that metformin
inhibits GI cancer development in vivo and in vitro via various
signal pathways (7–9). These pathways may explain how met-
formin influences the process of cancer development.
Despite these preclinical findings, clinical and epidemiological
studies have reported conflicting results on the association be-
tween metformin use and GI cancer development. Several meta-
analyses have indicated that metformin use reduced the risk of
developing GI cancers, including stomach, colon, liver, and
pancreatic cancers (10–13). By contrast, other studies that were
not included in these meta-analyses reported conflicting results.
de Jong et al. (14) reported that metformin use was not associated
with a decreased risk of any type of GI cancer, whereas Bodmer
et al. (15) reported that metformin use was not associated with a
decreased risk of colorectal cancer.
There are limited data on the association between metformin
use and GI cancer in Asian populations because previous studies
have generally focused on Western populations. However, Asian
populations have a rapidly increasing prevalence of type 2 DM
(16), and the burden of GI cancer is also increasing in Asian
countries (17), possibly because of changes in lifestyle and other
socioenvironmental factors. Therefore, it is important to examine
the association between metformin use and GI cancer de-
velopment among Asian individuals.
This study aimed to investigate the association between met-
formin use and GI cancer development among patients with
newly diagnosed, drug-naı̈ve type 2 DM using claims data from
theKoreanNationalHealth Insurance Service (KNHIS) database.
We also evaluated the effects of metformin use on the de-
velopment of GI cancer according to age, sex, cumulative met-
formin dose, and duration of metformin use.
METHODS
Data source
This retrospective study evaluated claims from the KNHIS da-
tabase that were made between January 1, 2005, and December
31, 2014. The KNHIS was launched by the Korean government in
February 1999 and is the only public medical insurance system in
Korea. This system is a compulsory social insurance system that
covers the entire Korean population. All clinics and hospitals
submit patient data, including information on diagnoses and
medical costs, to the KNHIS database. The KNHIS then provides
deidentified claims data to researchers. This study used cohort
data (NHIS-2020-1-389) provided by the KNHIS. The KNHIS
database has been used extensively for various epidemiologic
research, and its background and data configuration have been
described elsewhere in detail (18,19). The study protocol was
approved by the institutional review board of the National Health
Insurance Service Ilsan Hospital (2016-03-004). Written in-
formed consent from individual subjects was waived.
Study population
This study evaluated subjects with newly diagnosed type 2 di-
abetes, which was determined using the International Classifi-
cation of Diseases, 10th Revision, Clinical Modification codes
E11–E14 (16). These subjects had been prescribed one or more
antidiabetic drugs at least twice between January 2005 and De-
cember 2009.We selected subjects with newly diagnosed diabetes
by excluding subjects with previous claims for any antidiabetic
drugs or any diabetes-related claims codes during a 3-year
washout period before January 2005. Based on these conditions,
we identified 1,322,981 eligible subjects. We further refined the
cohort to exclude subjects with any cancer diagnosis before their
DM diagnosis, subjects who were not health insurance sub-
scribers, subjects whowere followed for,180 days after theirDM
diagnosis, and subjects who were exposed to metformin more
than once in the nonuser group. We also excluded subjects who
had received .3 insulin prescriptions from an outpatient clinic
during the study period because those subjects were presumed to
have uncontrolled type 2 diabetes at the time of diagnosis.
Definition of metformin exposure
Metformin users were defined as subjects who had been pre-
scribedmetformin for$180 days in a 365-day period.Metformin
nonusers were defined as subjects who had never been prescribed
metformin or who had receivedmetformin for,180 days during
the study period. Based on these definitions, we identified 578,207
metformin users and 149,605 metformin nonusers. We then
performed 1:1 propensity score matching according to age, sex,
region of residence, income level, and use of nonmetformin an-
tidiabetic drugs. The final analysis included a matched sample of
131,877 metformin users and 131,877 metformin nonusers
(Figure 1). To assess the effect of cumulative metformin exposure
on GI cancer development, we evaluated the cumulative pre-
scribed dose (mg/d3 days of use) and the cumulative treatment
duration (days), with subjects divided into tertiles for each
parameter.
Definitions and covariates
We investigated the development of 4 types of GI cancer (stom-
ach, colon, liver, and pancreatic cancers), which were identified
based on the corresponding International Classification of Dis-
eases, 10th Revision, Clinical Modification codes (stomach can-
cer: C16, colon cancer: C18–C21, liver cancer: C22, and
pancreatic cancer: C25). Caseswere considered to have developed
these cancers if their claim included the associated code and was
submitted between January 2005 and December 2014. The
follow-up durations were calculated from the date of study in-
clusion (the year in which the patient was diagnosed with DM or
started antidiabetic medication) to the date of GI cancer di-
agnosis, death, or the end of the study.
Economic status was divided into quartiles. The region of
residence was divided into 3 groups: Seoul (the capital city of
Korea), metropolitan cities (Busan, Daegu, Daejeon, Gwangju,
Incheon, and Ulsan), and rural areas. Other antidiabetic
medications included sulfonylureas, thiazolidinediones,
dipeptidyl peptidase-4 inhibitors, alpha-glucosidase inhibitors,
and meglitinide. Use of these nonmetformin antidiabetic
medications (a categorical variable) was identified using claims
data.
Statistical analyses
All data were analyzed using SAS software (version 9.4; SAS In-
stitute, Cary, NC).Metformin users and nonusers were compared
using Cox proportional hazard regression models, which were
adjusted for age, sex, year of enrollment, economic status, region
of residence, and the use of nonmetformin antidiabetic








medications. The results of the analyses were reported as hazard
ratios (HRs) and 95% confidence intervals (CIs). Differences were
considered statistically significant at P-values of ,0.05.
RESULTS
Baseline characteristics
The final cohort included a matched sample of 131,877 metfor-
min users and 131,877 metformin nonusers. Table 1 shows the
subjects’ age at diagnosis, sex, year of study enrollment, region of
residency, and nonmetformin antidiabetic drugs. Metformin
users were more likely to be older (mean age: 60.96 13.9 years vs
60.76 15.4 years), female subjects (50.1%vs 49.1%), and to have a
higher income. Metformin nonusers accounted for a higher
proportion of the subjects during the early study period. There
were no significant differences in the region of residency and the
use of nonmetformin antidiabetic drugs (with the exception of
alpha-glucosidase inhibitor use). The mean daily dose of met-
formin was 531 6 161 mg, the mean cumulative dose was
860,982 6 562,409 mg, and the mean cumulative treatment
duration was 1,618 6 911 days. Stomach, colon, and liver
cancers were less common among metformin users than among
metformin nonusers. However, pancreatic cancer was more
common among metformin users than among metformin
nonusers. Among 19,458 subjects diagnosed with GI cancers,
there were 197 subjects (1.01%) aged younger than 40 years (see
Table 1, Supplemental Digital Content 1, http://links.lww.com/
CTG/A410).
Cancer risks according to metformin exposure
Metformin users had lower incidence rates of stomach, colon, and
liver cancers, although they had a higher incidence rate of pan-
creatic cancer (Table 2). The multivariate analyses revealed that
metformin use was associated with significantly lower risks of
developing stomach cancer (HR: 0.841, 95%CI: 0.797–0.887; P,
0.001), colon cancer (HR: 0.865, 95% CI: 0.822–0.91; P, 0.001),
and liver cancer (HR: 0.709, 95% CI: 0.675–0.746; P , 0.001).
However, metformin use was associated with a significantly in-
creased risk of pancreatic cancer (HR: 1.335, 95%CI: 1.209–1.475;
P , 0.001).
Among subjects who were younger than 50 years of age
at diagnosis, metformin use was associated with significantly
lower risks of stomach (HR: 0.728, 95% CI: 0.605–0.877;
Figure 1. Study flowchart.
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Table 1. Baseline characteristics of the study population






Mean (SD) 60.9 (613.9) 60.7 (615.4)
0–14 536 0.4 438 0.3
15–20 344 0.3 469 0.4
20–24 543 0.4 449 0.3
25–29 1,640 1.2 740 0.6
30–34 2,721 2.1 1,566 1.2
35–39 3,989 3.0 3,903 3.0
40–44 7,784 5.9 6,682 5.1
45–49 12,252 9.3 11,655 8.8
50–54 14,136 10.7 15,061 11.4
55–59 15,366 11.7 13,925 10.6
60–64 16,275 12.4 20,061 15.2
65–60 19,031 14.4 20,123 15.3
70–74 14,177 10.8 18,320 13.9
75–79 11,365 8.6 11,283 8.6
$80 11,618 8.8 7,202 5.5
Sexa
Male 67,121 50.9 65,864 49.9
Female 64,756 49.1 66,013 50.1
Year of study enrollmenta
2005 32,338 24.5 30,969 23.5
2006 28,897 21.9 23,513 17.8
2007 25,700 19.5 24,672 18.7
2008 24,100 18.3 25,964 19.7
2009 20,842 15.8 26,759 20.3
Economic statusa
1st quartile 39,870 30.2 38,399 29.1
2nd quartile 24,320 18.4 23,832 18.1
3rd quartile 30,628 23.2 30,950 23.5
4th quartile 37,059 28.1 38,696 29.3
Region of residence
Seoul (capital city) 28,803 21.8 29,229 22.2
Metropolitan cities 32,893 24.9 33,180 25.2
Others 70,181 53.2 69,468 52.7
Antidiabetic drugs
Metformin
Yes 0 0 131,877 100
No 131,877 100 0
Sulfonylurea
Yes 61,341 46.5 61,399 46.6
No 70,536 53.5 70,478 53.4








P, 0.001) and liver cancers (HR: 0.634, 95% CI: 0.570–0.705;
P , 0.001) (see Table 2, Supplemental Digital Content 1,
http://links.lww.com/CTG/A410). Similarly, among subjects
who were 50 years of age or older at diagnosis, metformin use
was associated with the decreased risks of stomach (HR: 0.857;
95% CI: 0.810–0.906), liver (HR: 0.734, 95% CI: 0.694–0.777),
and colon cancers (HR: 0.871, 95% CI: 0.826–0.918), although
metformin use in this group was also associated with an in-
creased risk of pancreatic cancer (HR: 1.451, 95% CI:
1.304–1.615; P , 0.001).
Among both men and women, metformin users had lower
risks of stomach, colon, and liver cancers, although not of pan-
creatic cancer (see Table 2, Supplemental Digital Content 1,
http://links.lww.com/CTG/A410). Furthermore, the cumulative
dose and duration of metformin exposure seemed to influence its
effects on the development of GI cancers, with increasing expo-
sure generally associated with decreasing risks of developing all 4
types of GI cancers (see Table 3, Supplemental Digital Content 1,
http://links.lww.com/CTG/A410). The risks of stomach and liver
cancers were reduced at a cumulative metformin dose of
Table 1. (continued)






Yes 5,261 4.0 5,288 4.0
No 126,616 96.0 126,589 96.0
DPP4i
Yes 2,384 1.8 2,383 1.8
No 129,493 98.2 129,494 98.2
AGIa
Yes 11,455 8.7 10,994 8.3
No 120,422 91.3 120,883 91.7
Meglitinide
Yes 3,974 3.0 4,004 3.0
No 127,903 97.0 127,873 97.0
Daily metformin dose (mg)
Mean (range) 127,903 97.0 531 (161) —
Cumulative metformin dose (mg)
Mean (range) 860,982 (562,409) —
None 131,877 100 0 0
0–239,999 — — 19,775 15.0
240,000–1,200,000 — — 79,614 60.4
$1,200,000 — — 32,488 24.6
Cumulative duration of
therapy (d)
Mean (range) 1,618 (911) —
None 131,877 100 0 0
0–469 — — 19,424 14.7
470–1,999 — — 62,857 47.7






AGI, alpha-glucosidase inhibitors; DPP4i, dipeptidyl peptidase-4 inhibitors; TZD, thiazolidinediones.
aP, 0.001.
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240,000–1,200,000 mg, whereas the risks of colon and pancreatic
cancers were reduced at a cumulative dose of$1,200,000mg. The
risks of all 4 cancers were reduced when the exposure duration
was $2,000 days.
DISCUSSION
This study revealed that metformin use for newly diagnosed,
drug-näıve type 2 DM was associated with a reduced risk of de-
veloping GI cancer in the Korean population. Although metfor-
min use was associated with an overall reduced risk of developing
stomach, colon, and liver cancers, it was not associated with a
reduced risk of pancreatic cancer. However, subgroup analyses
revealed that the highest cumulative dose ($1,200,000 mg) and
longest exposure duration ($2,000 days) were associated with
reduced risks of all 4 GI cancers, with increasing cumulative dose
and duration tending to be associatedwith decreased cancer risks.
Findings from preclinical studies have indicated that metfor-
min has anticancer effects (20), which aremainly mediated by the
activation of AMPK. This activation downregulates the mTOR
complex and the IGF-1/Akt pathway, leading to p53-mediated
cell cycle arrest (21). Metformin inhibits the IGF-1 pathway
through AMPK-dependent phosphorylation of insulin receptor
substrate-1, which transmits signals from insulin and IGF-1 re-
ceptors to the phosphatidylinositide 3-kinase/Akt pathway and
subsequently downregulates mTOR signaling. Metformin also
affects p53-controlled pathways through AMPK-mediated p53
phosphorylation. Furthermore, metformin induces and alters the
expression of microRNAs which are associated with antitumor
mechanisms. These pathways help drive suppressivemechanisms
that contribute to cancer cell death. Several preclinical studies
have evaluated this issue using different cancer cell lines and
models. Kato et al. (22) reported that metformin inhibited the
proliferation of human gastric cancer cell lines and demonstrated
marked alteration of various microRNA expressions in vitro and
in vivo (7), which might also contribute to gastric cancer de-
velopment. Miyoshi et al. (9) reported that metformin inhibited
the proliferation of hepatocellular carcinoma cells and blocked
the cell cycle in G0/G1.
Based on these preclinical findings, clinical studies have
evaluated the association between metformin use and GI cancer
development, although the results have conflicted. A meta-
analysis of 7 cohort studies revealed thatmetformin use for type 2
DM was associated with a reduced risk of gastric cancer (HR:
0.763, 95% CI: 0.642–0.905; P5 0.0001) (23), whereas a separate
meta-analysis of 4 studies revealed that metformin use for type 2
DM was associated with a reduced risk of colorectal cancer (rel-
ative ratio: 0.63, 95% CI: 0.47–0.84; P 5 0.002) (13). Another
meta-analysis of 5 studies revealed that metformin use for type 2
DMwas associated with a reduced risk of liver cancer (odds ratio:
0.38, 95% CI: 0.24–0.59; P, 0.001) (10), and ameta-analysis of 4
studies reported that metformin use for type 2 diabetes was as-
sociated with a reduced risk of pancreatic cancer (relative ratio:
0.63, 95% CI: 0.46–0.86; P 5 0.003) (11). Therefore, the results
from our study are consistent with the findings of these meta-
analyses.
By contrast, studies which were deemed incompatible and
therefore not included in these meta-analyses indicated that
metformin use was not associated with a reduced risk of de-
veloping GI cancer. A population-based cohort study in the
Netherlands revealed that metformin use was not associated with
a decreased risk of stomach, liver, pancreatic, and colorectal
cancers (HR: 0.97, 95% CI: 0.82–1.15) (14) and also failed to
detect changes in the risk of cancer according to an increase in the
cumulative dose of metformin. This study included 35,654 sub-
jects (62.4%) with at least 1 year of antidiabetic medication-free
follow-up and 21,460 subjects (37.6%) with prevalent use of an-
tidiabetic medications. By contrast, this study included only
antidiabetes drug-näıve subjects to allow us to clearly determine
their effect. TheDutch studywas also based on a smaller subgroup
ofmetformin users (37,125metformin users vs 19,899metformin
nonusers), whereas our study, with 263,754 subjects, compared a
larger number of metformin users and nonusers. Another nested
case-control study from the United Kingdom revealed that based
on conditional logistic regression analyses, extensive use ($50
prescriptions) of metformin increased the risk of colorectal
cancer (odds ratio: 1.43, 95% CI: 1.08–1.90; P , 0.05) and was
Table 2. Risks of developing gastrointestinal cancers according to metformin use
Cancer cases Person-yr
Incidence rate of cancer
(%)
Incidence of cancer (per

















Stomach 2,872 2,459 899,702 903,861 2.18 1.86 319.2 272.1 0.860 0.841
(0.815–0.908)b (0.797–0.887)b
Colon 3,222 2,862 899,702 903,861 2.44 2.17 358.1 316.6 0.891 0.865
(0.847–0.937)b (0.822–0.910)b
Liver 3,770 2,678 899,702 903,861 2.86 2.03 419.0 296.3 0.708 0.709
(0.673–0.744)b (0.675–0.746)b
Pancreas 677 918 899,702 903,861 0.51 0.70 75.2 101.6 1.369 1.335
(1.239–1.511)b (1.209–1.475)b
CI, confidence interval; HR, hazard ratio.
aThe HRs were adjusted for age, sex, economic status, region of residency, and antidiabetic medications (sulfonylureas, thiazolidinediones, dipeptidyl peptidase 4
inhibitors, alpha-glucosidase inhibitors, and meglitinide). The results of the univariate and multivariate analyses were significant, relative to the metformin nonuser group.
bP, 0.001.








actually associatedwith an increased risk amongmen (15). In that
study, 920 subjects in the case group were patients who had an
incident diagnosis of colorectal cancer and had a history of type 2
diabetes before the cancer diagnosis. By contrast, this study
evaluated the incidence of cancer during a 5-year period in a
matched sample of 263,754 patients with newly diagnosed DM.
Therefore, we conclude that these methodological differences are
likely the source of the disagreement between our findings and
those of the studies described above.
This study revealed that a clear association between metformin
use and the pancreatic cancer development among patients with
newly diagnosed type 2 DM was lacking. However, metformin use
was associated with a reduced risk of pancreatic cancer in the sub-
groups with the highest cumulative dose and the longest exposure
duration. Early detection of pancreatic cancer is difficult, and it is
more likely to be diagnosed at an advanced stage (vs stomach, colon,
and liver cancers) because most patients do not experience symp-
toms until they have advanced pancreatic cancer (24). In addition,
the association betweenDMandpancreatic cancer is peculiar. Long-
term diabetes can be a risk factor for pancreatic cancer (25), and
patients with pancreatic cancer can rapidly develop diabetes (26).
The sequential association between these is not clear, and they have
become risk factors for each other. The effects of metformin use
might not be reflected among patients with newly diagnosed type 2
diabetes who already have pancreatic cancer. The complexity of this
association may explain the varying findings on the association be-
tween metformin use and pancreatic cancer. Furthermore, Lee et al.
(27) reported that dipeptidyl peptidase-4 inhibitors increased the
risk of pancreatic cancer among patients with newly diagnosed type
2 diabetes. However, there was no increasing trend according to
duration of exposure. We propose that the reason for the increased
risk of pancreatic cancer that was observed in our study could be the
peculiar concurrence of diabetes and pancreatic cancer, rather than
the influence of antidiabetes drugs.
This study evaluated the association between metformin use
and GI cancer in an Asian population because previous studies
have generally focused on European or American populations.
Asian populations have relatively high incidences of stomach,
colon, liver, and pancreatic cancers, with Eastern Asia having the
highest global incidence of stomach and liver cancers (2). Re-
gional differences in the prevalence of Helicobacter pylori in-
fection and dietary componentsmay influence the high incidence
of stomach cancer in Eastern Asia (2), whereas the high preva-
lence of chronic hepatitis B and C virus infections may influence
the high incidence of liver cancer (2). This study evaluated an
Asian population with newly diagnosed type 2 diabetes to clarify
the association between metformin use and GI cancers. This
study also analyzed subjects with newly diagnosed, drug-naı̈ve
type 2 diabetes. Previous studies that analyzed subjects who were
already diagnosed with diabetes or took antidiabetes medications
were somewhat limited in their ability to evaluate the effect of
metformin. Therefore, our results better reflect the effect of
metformin on GI cancer.
This study has some limitations. First, we retrospectively
evaluated claims data from the NHIS database, which does not
include laboratory test results. Thus, it was impossible to consider
the magnitude of DM control because we did not have available
data on hemoglobin A1c levels. Second, the claims do not contain
important GI cancer-related information, such as family medical
history, obesity, drinking, and smoking (27–30), which may have
introduced some bias into our findings. Third, this study had a
relatively short follow-up duration because it takes an average of
10–20 years for normal colonic crypts to develop into overt ad-
enocarcinoma (31). Thus, a study with a longer follow-up period
might be needed to more accurately define the association be-
tween metformin use and GI cancer development. Fourth, this
study did not consider the duration of use for other antidiabetic
medications, which were only considered categorical variables
(any use or nonuse) for the adjustment of our analyses.
In conclusion, our findings suggest that metformin use could
be associated with a reduced risks of stomach, colon, and liver
cancers and a reduced risk of pancreatic cancer in some sub-
groups. Therefore, metformin has benefit as a first-line treatment
for type 2 DM, based on its anticancer and glucose-lowering
effects. A further role in cancer risk reduction could be studied in
controlled trials.
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Study Highlights
WHAT IS KNOWN
3 Metformin has had anticancer effects in preclinical testing.
3 Clinical studies have failed to confirm this effect in GI cancer.
WHAT IS NEW HERE
3 Metformin use was associated with reduced stomach, colon,
and liver cancer risks among newly diagnosed type 2diabetes
patients.
3 Metformin use at the highest cumulative dose ($1,200,000
mg) and the longest duration ($2,000 days) reduced
pancreatic cancer risk among newly diagnosed type 2
diabetes patients.
TRANSLATIONAL IMPACT
3 Metformin might provide added values that reduced risks of
GI cancers for managing newly diagnosed type 2 diabetes.
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